Slideshow

Diabetes News Roundup: October 2018

Author(s):

Mark L. Fuerst

Highlights include: "Artificial pancreas" improves glucose control; T1DM often misdiagnosed as T2DM; and a genetic connection for “type 1.5 diabetes.” 

Related Videos
Viet Le, DMSc, PA-C | Credit: APAC
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
Richard Pratley, MD | Credit: Advent Health Diabetes Institute
Rahul Aggarwal, MD | Credit: LinkedIn
Related Content
Stock image of body weight scale. | Credit: iStock
December 4th 2024

SURMOUNT-5: Tirzepatide Bests Semaglutide in Head-to-Head Weight Loss Trial

Patrick Campbell
Diabetes Dialogue: News and Updates in Diabetes at AHA 2024
November 21st 2024

Diabetes Dialogue: News and Updates in Diabetes at AHA 2024

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
HCPLive Endocrinology Month in Review: November 2024
December 1st 2024

Endocrinology Month in Review: November 2024

Patrick Campbell
Diabetes Dialogue: Diabetes Tech Updates in October 2024
November 11th 2024

Diabetes Dialogue: Diabetes Tech Updates in October 2024

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Dhruv Kazi, MD | Credit: PCSK9 Forum
November 18th 2024

More than 50% of US Adults Considered Eligible for Semaglutide with Current Labeling

Patrick Campbell
Intensive Blood Pressure Regimen Lowers CVD Risk in People with T2D | Image Credit: American Heart Association
November 16th 2024

Intensive Blood Pressure Regimen Lowers CVD Risk in People with T2D

Connor Iapoce
© 2024 MJH Life Sciences

All rights reserved.